{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "PGNY",
  "name": "Progyny, Inc.",
  "url": "https://orbyd.app/dossiers/PGNY/",
  "json_url": "https://orbyd.app/dossiers/PGNY.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Fertility-benefits re-rate broke out rather than stalled: PGNY cleared the $28.75 shelf and printed a new 52-wk high $33.06, trading ~$31.9–32.5 after KeyBanc lifted its target to $35 on 7/13. Price now sits above the $30.73 consensus, so the 2026-07-30 Q2 print is the binary that either validates the breakout or funds a round trip to $28.",
  "invalidation_trigger": "A weekly close below $28 forfeits the July breakout shelf (the old $28.75 52-week high, now first support) and returns the tape to the June range. Secondary: a top-client non-renewal disclosed at the 2026-07-30 Q2 print, or a final excepted-fertility rule that narrows the standalone category or the $120K lifetime cap.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "ai-enterprise-software",
    "precision-biotech-therapeutics",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Price action: the early-June pullback-to-50-DMA (~$24) entry never came; name held its bid and ground $25->$27 toward the $28.75 high. Clean entry = confirmed $28.75 breakout-retest OR pullback toward the rising 50-DMA, not a mid-range chase into the catalyst vacuum.",
    "Trim/management discipline (research frame): RSI is a review flag only; structure stays intact while retention ~100% and policy momentum builds. Structural cracks = client loss, excepted-benefits rule reversal, or a weekly close below the 50-DMA.",
    "THEME FIX (recurring — has been overwritten twice by automated theme tagging, 2026-06-05 and 2026-06-08): PGNY is a fertility/family-building BENEFITS MANAGER selling a carve-out to self-insured employers. It is NOT a therapeutics biotech. Do not accept 'biotech-precision-therapeutics'.",
    "Earnings blackout: Q2 2026 print 2026-07-30 after the close (company IR / TipRanks). MarketBeat's aggregator shows an estimated 8/06 — treat 7/30 as primary and avoid fresh entries inside 3 trading days of it.",
    "Prior 'MATURING, wait for the $24 pullback' framing was overtaken by the tape: the pullback never came and the stock broke out to a new 52-week high instead. Documented lesson — a low-velocity grind toward a multi-month high in a name with rising targets resolves up more often than it mean-reverts.",
    "Q1 (2026-05-07) figure convention differs by source: press release Adj EPS $0.50 / rev ~$328.5M; some aggregators show $0.48 / $318.4M. The FY26 guide RAISE to $1.98-$2.09 (vs ~$1.32 Street) is the unambiguous datapoint.",
    "Trim discipline: this is a turnaround re-rate, not a retail squeeze — the RSI>75 auto-trim band does not apply. High RSI is a review flag only. Structural cracks that matter: top-client loss, rule reversal, weekly close under the breakout shelf.",
    "Price is now ABOVE the $30.73 consensus target. Sell-side has to chase to keep the re-rate funded; watch for post-print target revisions as the tell on whether the analyst leg has more room."
  ],
  "body_markdown": "## Current Thesis\nThe fertility-benefits carve-out re-rate did not stall out into a summer range — it broke out. Progyny cleared the $28.75 prior 52-week high in early July and printed $33.06, trading around $31.93–$32.47 on 2026-07-17 against $29.45 on 2026-07-01. The proximate spark was KeyBanc lifting its target to $35 from $30 on 2026-07-13, worth a 3.5% session gain, on the same day the comment window closed on the proposed excepted-fertility-benefits rule. Two things follow from that. First, the \"grind toward the high in a catalyst vacuum\" read from June resolved upward, and the theme deserves an accelerating tag again rather than a late-cycle one. Second, at ~$32 the stock now trades roughly 4% *above* the $30.73 consensus target across 13 analysts, which means the marginal buyer is paying for a beat-and-raise that has not been printed yet. The 2026-07-30 Q2 report is where that gets settled.\n\n## Bull Case\n- **Breakout is confirmed, not a wick.** The 50-day range spans $22.55–$32.36; price is at the top of it and has held above the old $28.75 shelf for multiple sessions. Year-to-date +24.3% off a $16.10 52-week low.\n- **2026-05-07 Q1 reset the model.** Adjusted EPS $0.50 versus a $0.26 estimate; revenue ~$328.5M. FY26 adjusted EPS guidance lifted to **$1.98–$2.09** against roughly $1.32 of Street modeling — a guide set ~50% above consensus, which is what a genuinely mispriced turnaround looks like.\n- **Underlying growth re-accelerated once the client-transition drag lapped.** Q1 revenue +12.2% YoY excluding prior-year transition revenue. The 2024 Amazon non-renewal that produced the $16 handle is now in the base.\n- **Policy leg has a hard effective date.** The DOL/HHS/Treasury proposal published 2026-05-13 creates a standalone \"excepted fertility benefits\" category with a $120K lifetime cap per worker, offerable without primary-plan enrollment. Comments closed 2026-07-13; the rule targets 2027-01-01. That directly widens the addressable employer base for a carve-out vendor.\n- **Analyst tape is still being revised up.** KeyBanc $35 (2026-07-13) follows Truist $33 (6/22), BofA $31 (6/02), Citizens $31, Canaccord Hold→Buy $30 (5/19), Barclays $27 (5/18). Ratings run 1 strong buy / 10 buy / 2 hold.\n- **Down-market product is live.** Progyny Select, the first fully-insured supplemental fertility and women's-health plan for small employers, launched 2026-04-16 — pulling a FY2027 opportunity into the current selling season.\n- **Short base is covering.** 6.37% of float short, 3.04 days to cover, short interest down 6.48% in the latest update. Roughly $200M of buyback (8.8M shares) already retired.\n\n## Bear Case\n- **Price is through the target band.** Consensus sits at $30.73 versus ~$32 spot, implying ~4% downside on the sell-side's own math. Absent post-print revisions, the analyst leg is spent.\n- **Print risk in 11 days.** Q2 lands 2026-07-30 after the close. A stock at a 52-week high, above consensus, with a 41.5x P/E and 2.53 PEG has no cushion for an in-line quarter — an in-line result is a de-rate here.\n- **Client concentration is the recurring scar.** One top-employer non-renewal is exactly what took this from the mid-$30s to $16 in 2024. That headline can arrive on the call.\n- **Final rule can be narrowed.** The excepted category or the $120K cap could be trimmed between now and 2027-01-01, removing a leg the multiple is partly discounting.\n- **The name is showing up on overbought screens.** A 2026-07-15 Benzinga piece listed Progyny among health-care stocks flagged as stretched — a crowding marker, not a thesis, but it dates when the retail bid arrived.\n- **$2.50B market cap on a services multiple.** There is no asset backstop; the entire valuation is contracted employer lives and utilization economics.\n\n## Setup & Price Structure\nThe relevant structure is a two-stage advance: the May base off $16.10, then a July expansion leg through the $28.75 shelf into $33.06. Price above a rising 50-DMA (mid-to-high $20s given the $22.55 low of the 50-day range), and the old high now serves as the first line of defense near $28.75. A hold above $28 keeps the breakout intact and frames the $33.06 high as a base rather than a top. The specific failure pattern to avoid paying up for. The entry is genuinely late-cycle within this leg: buying $32 to defend $28 is a ~13% structural risk into a dated binary, which caps reasonable sizing regardless of how clean the chart looks. Position size should reflect the print, not the trend.\n\n## Catalyst Calendar (next 30 days)\n\n- **Ongoing through August** — Post-print target revisions. With spot above the $30.73 average, whether the 13-analyst cluster chases into the mid-$30s is the cleanest read on whether the re-rate has a third leg.\n- **No dated regulatory milestone before 2027-01-01**, the proposed effective date of the final rule.\n\n## Elapsed catalysts\n\n- **2026-07-30 (after close)** — Q2 2026 earnings and call. Primary binary. Watch: FY26 adjusted EPS guide versus the $1.98–$2.09 range, any commentary on 2027 selling-season bookings, client retention (has been running ~100%), and Progyny Select attach since the 4/16 launch. Note the date convention: company IR and TipRanks show 7/30; MarketBeat's aggregator estimates 8/06. Treat 7/30 as the live date. *(passed 10d ago)*\n- **2026-07-13 (elapsed)** — Comment period on the excepted-fertility-benefits proposal closed. No day-of market reaction beyond the KeyBanc revision; the rule now sits with the agencies. *(passed 27d ago)*\n\n## What Would Change Our Mind\nA weekly close below $28 ends the breakout read outright — that level is the old 52-week high and the only structure between spot and the June range. Beyond price: a Q2 report that holds FY26 guidance flat instead of raising it again would confirm the $1.98–$2.09 range as a ceiling rather than a floor, which is the specific thing the current multiple is not priced for. A disclosed top-client non-renewal, at the print or in an 8-K before it, breaks the thesis in a single headline given the 2024 precedent. On the policy side, a final rule that either eliminates the standalone excepted category or cuts the $120K lifetime cap materially removes the structural TAM expansion the July revisions were partly underwriting. Conversely, a raise on 7/30 with 2027 bookings commentary and the sell-side cluster moving toward $35+ would re-open the case for adding into strength rather than treating $33 as the ceiling.\n\n## Correlation Notes\nProgyny is close to a pure single-name expression — there is no tradable fertility-benefits cohort to cross-confirm the breakout, which is a real weakness in the setup. Its loosest peers are employer-benefits and specialty-carve-out managers (HIMS in consumer telehealth, ACCD in navigation, and the broader managed-care complex UNH/ELV/CI as a sentiment backdrop), but none of them price fertility utilization. The stock trades more like a small-cap turnaround than a health-care staple: high beta to the Russell 2000 and to rate-sensitivity in unprofitable-to-profitable small caps, and essentially uncorrelated to IVF clinic operators or pharma. The policy leg does introduce a shared driver with anything levered to employer-sponsored benefit design, but Progyny is the only listed name where a standalone excepted-benefit category translates directly into new contracted lives. Practical consequence: no peer breakout will confirm this move, and no peer breakdown will warn ahead of it. The 7/30 print carries the full information load.",
  "first_seen": "2026-05-19",
  "last_analyzed": "2026-07-19T11:11:52+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}